Alto Neuroscience, Inc. (ANRO)
NYSE · USD · Healthcare · Biotechnology
$22.11 (+0.64%) as of
Key statistics
- Market cap
- 867.64M
- Forward P/E
- -6.94
- EPS (TTM)
- -2.32
- Dividend yield
- 0.00%
- 52-week range
- 10.20 – 37.48
- Beta
- 1.34
- Profit margin
- 0.00%
- Analyst target
- $38.67
- Volume
- 550.06k
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Mountain View, CA, United States
- Employees
- 68
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.